Getting Started with HRT: The Definitive Guide

How do you get started with menopause HRT?

Start by telling a clinician which symptoms interfere with your life and asking what treatment fits your stage of menopause, medical history and preferences. Hormone replacement therapy (HRT), also called menopausal hormone therapy, uses estrogen, often with a progestogen, to treat menopause symptoms. It is not one medicine or one standard schedule. Tablets, patches, gels and vaginal preparations have different purposes and instructions. [1], [3]

For troublesome hot flashes and night sweats, systemic treatment, which delivers hormone around the body, may be an option. For vaginal dryness or pain with sex, low-dose local vaginal estrogen may be enough, or may be added to systemic treatment. Having a uterus usually means systemic estrogen needs adequate protection for the uterine lining. Your clinician should also discuss alternatives and whether you still need contraception. [1], [4], [8]

You do not need to choose a brand, request a particular dose or prove you can tolerate symptoms before the appointment. Bring a short account of what has changed and what you want help with. This guide concerns menopause care; gender-affirming hormone treatment and fertility treatment require their own assessment. [1], [3]

Which decisions matter before you start?

This is a conversation checklist, not a test you must pass. Product availability and authorization differ between countries. The UK guidelines cited here explain common clinical decisions; they do not establish Canadian or US approval for a particular product. [4], [7], [8]

Do your symptoms and period history fit menopause?

Perimenopause is the transition when periods change and menopause symptoms may begin. You can still ovulate and become pregnant. Menopause is generally identified after 12 months without a period when hormonal contraception does not explain the absence. After that, the stage is called postmenopause. A hysterectomy or hormonal contraceptive can make period history less informative, so describe symptoms and treatment history too. [1], [4]

In otherwise healthy people aged 45 or over with a typical pattern, NICE generally identifies menopause from symptoms and menstrual history without hormone testing. A normal estradiol result is not a reason by itself to dismiss symptoms. Testing has specific uses, including assessment of suspected menopause under 45; under 40, possible premature ovarian insufficiency needs a separate diagnostic and treatment discussion. These exceptions matter more than an online claim that everyone needs, or nobody needs, blood tests. [1]

Describe timing rather than labelling every change as hormonal: when it began, whether it varies with your cycle and whether it wakes you at night. Fatigue, poor sleep, low mood and concentration problems can have several causes. HRT assessment should leave room to investigate other explanations and provide additional treatment when needed. NICE separates menopause-associated depressive symptoms from diagnosed depression, which needs its own appropriate care. [1], [3]

How does having a uterus change your treatment?

Estrogen can stimulate the endometrium, the lining inside the uterus. When you have a uterus, systemic estrogen without adequate protection increases the risk of lining overgrowth and cancer. A progestogen generally supplies that protection. Progesterone is one member of this hormone group; it is not the only option. Combined HRT contains both components, either in one preparation or as separately prescribed medicines. [1], [8]

After a total hysterectomy, estrogen-only HRT is usually offered. Tell the clinician if your operation was partial or if you have endometriosis, because the history may affect the choice. Removing the ovaries is a different operation from removing the uterus. Do not infer your need for a progestogen from whether you still have ovaries or from whether you have bleeding. [1], [7], [8]

A suitable levonorgestrel IUD can sometimes provide both contraception and the progestogen component of HRT. Confirm the exact device, insertion date and purpose. Its contraceptive lifespan and the period supported for uterine protection with estrogen are different questions. The UK FSRH guideline supports a 52 mg levonorgestrel IUD for up to 5 years of HRT endometrial protection; this is a named UK recommendation, not a universal license for every hormonal IUD. [4], [8]

If progesterone causes unwanted effects, ask about alternatives rather than silently removing it from the plan. Compounded progesterone cream is not a reliable substitute for prescribed endometrial protection. BMS describes variable absorption and insufficient evidence for protection with these preparations. Changing an oral capsule to vaginal use is also a prescribing decision, with off-label status and evidence limitations to discuss. [8], [10]

Is systemic or local treatment the better starting point?

Systemic treatment reaches the circulation to treat symptoms such as hot flashes. It may be taken orally or delivered through the skin. Local vaginal estrogen treats vaginal and related urinary symptoms, with much less systemic absorption. NICE offers vaginal estrogen for these symptoms even when systemic HRT is already being used. Moisturizers and lubricants can be used alongside it. [1], [9]

Local low-dose vaginal treatment is not a treatment for hot flashes. Equally, a systemic prescription does not guarantee that dryness or painful sex will settle. Be specific about the symptom you are treating and tell the clinician if it persists. A history of breast cancer calls for a more individual discussion, especially during aromatase-inhibitor treatment; do not apply general low-risk statements to that situation. [1], [9]

Vaginal does not always mean local. Femring is a US vaginal ring approved for menopausal hot flashes as well as vaginal symptoms, and has systemic estrogen effects. Its label discusses progestin use with a uterus. Check the actual product rather than treating all rings, creams and tablets as interchangeable. [7]

How do schedules and contraception fit together?

In sequential combined HRT, estrogen continues through the treatment cycle and progestogen is taken for a prescribed portion of it. A withdrawal bleed commonly follows the progestogen course. This is often the starting approach when periods continue or the last period was recent. In continuous combined HRT, both components are provided continuously, with the aim of avoiding a monthly withdrawal bleed. It is usually used after menopause; early irregular bleeding can still occur. [5], [6]

The NHS describes its sequential combined products as using progestogen for 10 to 14 days of a 28-day cycle. BMS gives preparation-specific minimum durations, including different requirements for micronized progesterone and some synthetic progestogens. These descriptions are not interchangeable instructions. A calendar-month regimen is also not automatically the same as a 28-day pack. Use the written schedule for your prescribed medicines, not a generic diagram or another person's routine. [2], [5], [8]

HRT does not provide contraception. If pregnancy is possible and you wish to avoid it, make contraception part of the initial plan. Hormonal contraception can also obscure whether menopause has occurred. FSRH advises choosing and stopping contraception according to age, method and circumstances; a missed period on hormones is not sufficient evidence that contraception is no longer needed. [4]

Some contraceptives can be used alongside HRT. A contraceptive pill or implant, however, should not automatically be assumed to provide the endometrial protection needed with systemic estrogen. Eligible people may use combined hormonal contraception instead of HRT in some circumstances; do not add HRT to it on your own. Ask the prescriber to reconcile the complete plan, including each medicine's purpose. [4]

What benefits and risks should you discuss?

Hormone therapy is an effective treatment for troublesome vasomotor symptoms and can prevent bone loss and fractures. Whether that makes it a good choice for you depends on the symptoms being treated, baseline risks, formulation, route and duration. Relief of one symptom does not guarantee that every sleep, mood, weight or sexual concern will improve. There are separate treatments for symptoms that persist and nonhormonal options if HRT is unsuitable or unwanted. [1], [9], [10]

The 2022 North American Menopause Society statement describes a generally more favorable benefit-risk balance for symptomatic people younger than 60 or within 10 years of menopause onset who have no contraindications. Starting later calls for closer consideration of age-related absolute risks. This is a framework for discussion, not a guarantee of safety or a rule that everyone must begin before a birthday. The statement's abstract was checked for this guide; it does not supply a personalized risk estimate. [9]

Discuss previous breast or other hormone-sensitive cancer, blood clots, stroke, heart disease, liver disease, uncontrolled blood pressure and unexplained vaginal bleeding. These are reasons for clinical assessment, sometimes specialist advice or alternatives, rather than an automatic prescription. Oral and transdermal estrogen have different clot-risk considerations; NICE advises considering a transdermal route where venous-clot risk is increased. A patch does not remove every risk or make a contraindicated treatment suitable. [1], [3], [7]

Ask for risks in terms you can use: which outcome, with which medicine, compared with what, over how long, and how your history changes the starting risk. Breast-risk discussions should distinguish combined treatment from estrogen-only treatment and systemic treatment from low-dose local therapy. This overview does not transfer a single study's risk numbers to every HRT product. The WHI guide explains why formulation and study population matter. [1], [7], [9]

HRT is not a general anti-aging treatment or a prescription to prevent dementia or cardiovascular disease. NICE specifically advises against offering it for primary or secondary cardiovascular prevention or dementia prevention. If you prefer to avoid hormones, ask about menopause-specific cognitive behavioural therapy and suitable nonhormonal medicines. The choice should address your main symptoms and any monitoring the alternative requires. [1], [7]

What should happen during the first few months?

Agree on what improvement would look like before you start: fewer disruptive hot flashes, fewer nights awake with sweating, or less vaginal discomfort. Some symptoms may begin improving in days or weeks; NHS guidance notes that HRT can take up to 3 months to work fully. That is not a promise of complete relief, and troublesome unwanted effects are a reason to contact the prescriber earlier. [3], [5], [6], [10]

NICE recommends reviewing treatment at 3 months, then annually, with earlier review when clinically needed. Review should cover benefit, tolerability and whether the treatment still fits. If symptoms do not improve or unwanted effects persist, the clinician may reassess the diagnosis, instructions, formulation or dose, or seek specialist input. Keep up with nationally recommended screening rather than assuming HRT replaces it. [1], [3]

Headaches, nausea, breast tenderness, dizziness and mood changes can occur with estrogen or progestogens. They may settle, but their impact matters. Record when they occur and whether they relate to a progestogen course or treatment change. Ask the pharmacist about missed-dose instructions, patch detachment and practical use; those instructions depend on the product. Do not take extra doses or alter the progestogen schedule to compensate without the relevant advice. [2], [5], [10]

Which bleeding should you report?

Distinguish an expected withdrawal bleed on a sequential schedule from unscheduled bleeding, which occurs outside the expected pattern. Tell your clinician about unexpected bleeding and record its start, duration and amount. Do not assume bleeding proves that the estrogen dose is too high or progesterone too low. Assessment considers the regimen, adherence, examination findings and individual cancer risk. [2], [5]

NICE's 2026 advice says bleeding is common during the first 6 months of systemic HRT or within 3 months of changing its dose or preparation. Seek medical help promptly for unscheduled bleeding beyond those windows. BMS also recommends earlier investigation for heavy or prolonged bleeding and certain risk factors, regardless of how recently HRT began. These windows explain context; they are not instructions to wait while concerning bleeding continues. [1], [2]

If bleeding is very heavy, you feel faint or unwell, or you have severe pain, seek urgent care. New bleeding after a settled bleed-free period should also be discussed promptly. Your clinician may arrange an examination, ultrasound or other tests; an ultrasound finding and your history guide what follows. Keep the bleeding discussion separate from routine dose adjustments, and do not rely on a forum to rule out a serious cause. [2], [7], [10]

For sudden chest pain, breathlessness, stroke-like symptoms or a painful swollen leg, seek urgent medical assessment rather than waiting for a routine review. These are warning symptoms discussed in estrogen prescribing information, not expected adjustment effects. [7]

What should you bring to the first appointment?

Prepare a one-page summary. Include your main symptoms and how they affect daily life; your recent period dates and any unusual bleeding; whether you have a uterus and ovaries; and relevant operations. Add medical and family history, current contraception and every medicine, supplement or herbal product you use. If you have an IUD, bring its name and insertion date. These details help assess treatment and contraception together. [2], [3], [4]

Use the appointment to get a workable plan. Ask: What is each medicine treating? How is my uterine lining protected? What exactly do I take or apply, and when? What bleeding is expected? Which symptoms require earlier contact? When is the review? Repeat the instructions back, especially if estrogen and progestogen have different schedules. Ask whom to contact if the prescription is unavailable or difficult to use. [2], [3], [5]

You can also ask about alternatives, cost and whether a specialist opinion would help. Choosing to defer HRT or try a nonhormonal option does not close the discussion permanently. Benefits and risks should be revisited as symptoms, health and preferences change. Duration is individualized rather than decided by an automatic stop date. See stopping or tapering HRT for that later conversation. [1], [9]

What do public community accounts add?

Three public r/Menopause discussions checked for this guide describe mixed beginnings: some participants report fewer hot flashes or better sleep, others describe incomplete benefit or feeling worse, and several ask about bleeding and managing two medicines. These are selected experiences, not a survey or a prediction of your response. [11], [12], [13]

The practical theme is preparing a useful follow-up account. One symptom may improve while another remains troublesome. Bleeding can produce uncertainty even when other symptoms improve. Unwanted effects deserve the same attention as benefit. Online suggestions to raise a dose, change a route or skip a component are not validated by those discussions and are not used as instructions here. [11], [12], [13]

Bring concerns from a discussion to your clinician as questions: could this be an unwanted effect, is the bleeding pattern expected for my regimen, and do the instructions need clarifying? A supportive account can help you feel less alone; it cannot establish endometrial protection, diagnose the cause of bleeding or decide which medicine you need. [2], [8], [11], [13]

What is useful to track between visits?

Keep a brief record that makes the treatment understandable. Note the exact product, route, prescribed schedule, start date and changes. Record missed or delayed doses and application problems honestly. For sequential treatment, include the dates the progestogen course begins and ends. This helps distinguish a treatment change from a change in how the medicine was used. [2], [5]

Track your main symptoms consistently, using simple descriptions such as mild, moderate or disruptive. Add sleep interruptions, bleeding dates and amount, and unwanted effects. A short weekly summary is often easier to discuss than pages of disconnected notes. Include what has improved as well as what has not, and keep urgent symptoms out of the wait-for-review routine. [2], [3], [10]

At follow-up, compare the record with the goals you agreed on. A symptom log supplies context; it does not prove that HRT caused every change or establish a hormone target. Discuss meaningful benefit and tolerability with the prescriber. [1], [3]

Doserly tracks the schedule you and your clinician choose. It does not recommend doses.

Common questions about starting HRT

Do I have to wait until my periods stop?

No. HRT can be used for menopause symptoms during perimenopause, while periods continue. Your menstrual history, contraception and any unusual bleeding help the clinician choose an appropriate schedule, often sequential combined treatment in this setting. Bring the date and pattern of recent periods and the actual contraceptive method. The schedule section explains why these decisions belong together: HRT does not prevent pregnancy, and a friend’s continuous or sequential calendar is not a prescription for your stage. [4], [5]

Do I need a hormone panel before a prescription?

Not routinely for typical menopause in an otherwise healthy person aged 45 or over, according to NICE. Younger age, an unusual presentation or another suspected condition may warrant a different assessment or tests. Ask which clinical question an analysis would answer and whether its result would change the plan. The symptoms and stage section separates menopause identification from other health questions; needing investigation for anemia or thyroid disease is different from needing an estradiol target to qualify for treatment. [1]

Can I use vaginal estrogen without taking systemic HRT?

Yes. Low-dose local vaginal estrogen can treat vaginal symptoms on its own and may also be used alongside systemic HRT when local symptoms persist. Confirm the exact formulation and intended purpose rather than relying on the word vaginal: Femring is a systemic vaginal ring and needs a different assessment. A breast-cancer history also requires a separate discussion. The treatment-choice section helps you identify the local versus systemic question before agreeing on the product and follow-up. [1], [7], [9]

Will progesterone in my contraceptive pill protect my uterus?

Do not assume it will. FSRH does not recommend the progestogen-only pill or implant as endometrial protection with estrogen-only HRT. An appropriate 52 mg levonorgestrel IUD can have that role under a specified guideline and replacement interval, which may differ from its contraceptive duration. Bring the device name and insertion date or contraceptive pack. Ask the prescriber to confirm both purposes in writing; the schedule section explains why contraceptive effectiveness and uterine protection are related but separate decisions. [4]

What if the progestogen makes me feel unwell?

Contact the prescriber and describe the symptoms, their timing and whether they occur during a particular part of the schedule. Another preparation or treatment arrangement may be discussed, but the whole regimen needs review. If you have a uterus, dropping the protective component while continuing systemic estrogen can create risk. Do not substitute a compounded cream or change the route yourself. The treatment-choice section explains the protection requirement, and the review should address both tolerability and a usable protective plan. [8], [10]

Is any bleeding during the first six months harmless?

No. Early bleeding can be common, but heavy or prolonged bleeding, relevant risk factors or a concerning pattern can require assessment sooner. Report the pattern, timing, actual regimen and any missed protective treatment. NICE’s starting and change-related windows help interpret the situation; they do not guarantee harmless bleeding or replace the BMS assessment pathway. The bleeding section explains when ordinary settling-in advice is insufficient. Follow the contact plan you receive rather than waiting automatically for a calendar deadline. [1], [2]

What if I feel no better at the first review?

Tell the clinician which symptoms remain, which improved and what unwanted effects or practical problems occurred. Bring the actual product, instructions and a brief record of use; symptom benefit and poor tolerability can coexist. The next step may be checking application, reviewing treatment, investigating another cause or seeking specialist advice. More estrogen is not the automatic answer to every persistent symptom. The follow-up section explains what the first review should resolve and how to agree on a clear next step. [1], [3], [10]

Do I have to stop after a fixed number of years?

No single duration fits everyone. NICE recommends discussing duration when treatment begins and reconsidering benefits, risks and preferences at reviews. Persistent symptoms may support continued treatment after an individual discussion; new illness, bleeding, adverse effects or a change in priorities may alter that decision. Ask what would trigger an earlier reassessment and what alternatives would be considered if you wanted to stop. The follow-up section describes review as an ongoing decision rather than a guarantee of indefinite treatment or a universal deadline. [1], [9]

Glossary

Terms you may hear during a menopause appointment.

HRT / menopausal hormone therapy

Hormone treatment used for menopause symptoms; the terms refer to the same care context here.

Perimenopause

The transition when ovarian hormone patterns and periods change and menopause symptoms can begin.

Menopause

The end of menstrual periods because of loss of ovarian activity, generally identified after 12 months without a period when no other cause explains it.

Postmenopause

The stage after menopause has occurred.

Vasomotor symptoms

Hot flashes and night sweats associated with menopause.

Estrogen

A hormone group involved in reproductive tissues, temperature regulation and bone health; used in many menopause treatments.

Estradiol

A type of estrogen used in several oral, transdermal and vaginal medicines.

Progestogen

The hormone group that includes progesterone and synthetic progestins; often used to protect the uterine lining with systemic estrogen.

Progesterone

One progestogen, available in prescribed formulations; its route and schedule affect how it is used.

Progestin

A synthetic progestogen, such as levonorgestrel or medroxyprogesterone acetate.

Uterus

The womb; the organ whose inner lining responds to estrogen and progestogens.

Endometrium

The lining inside the uterus.

Endometrial protection

Treatment that limits estrogen-driven overgrowth of the uterine lining, usually a suitable progestogen when systemic estrogen is prescribed.

Endometrial hyperplasia

Overgrowth of the uterine lining; some forms can progress to cancer.

Hysterectomy

Surgery to remove the uterus; total and partial operations differ.

Oophorectomy

Surgery to remove an ovary or both ovaries; it is different from removal of the uterus.

Systemic treatment

Treatment whose hormone reaches the circulation to act around the body.

Low-dose local vaginal estrogen

Vaginal estrogen intended mainly to treat vaginal and related urinary symptoms, with much less systemic absorption.

Transdermal

Delivered through the skin, for example by a patch or gel.

Combined HRT

HRT that supplies estrogen and a progestogen, in one product or as separate components.

Sequential combined HRT

A schedule with estrogen through the cycle and progestogen during a prescribed part of it.

Continuous combined HRT

A schedule supplying estrogen and progestogen continuously, usually aiming to avoid a monthly withdrawal bleed.

Withdrawal bleed

Bleeding commonly occurring after the progestogen course in a sequential schedule.

Unscheduled bleeding

Bleeding outside the expected pattern for the treatment schedule.

IUD

An intrauterine device; certain levonorgestrel devices can have contraception and HRT protection roles with different replacement rules.

Contraindication

A condition or circumstance in which a treatment should not be used.

Absolute risk

The chance of an outcome in a defined group over a stated time; it is different from a relative change in risk.

Off-label use

Use outside the indication, route or schedule authorized in the product's local prescribing information.

Compounded preparation

A medicine individually prepared rather than supplied as the equivalent approved finished product; approval of an ingredient does not establish the preparation's safety or effectiveness.

Premature ovarian insufficiency

Loss or marked reduction of ovarian function before age 40, requiring a specific assessment and treatment discussion.

How was this guide researched?

Source selection and limits

We checked the original NICE recommendations, BMS bleeding recommendations and endometrial-protection document, official NHS medicine pages and the FSRH over-40 contraception guideline on October 2, 2026. The North American Menopause Society position statement was checked at abstract level on PubMed; the Femring example was checked in the full US prescribing information on DailyMed. The source directory identifies these access levels and locations. [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]

This guide explains decisions, not individualized doses or conversion between products. It presents no invented regimen, treatment success rate or universal blood-hormone target. UK recommendations are identified as such; they do not certify local authorization elsewhere. The three public community discussions illustrate questions and mixed experiences, without usernames, copied anecdotes or an assumed response rate. [11], [12], [13]

Sources